Journal Browser

Journal Browser

Special Issue "Molecular Mechanisms in Multiple Sclerosis"

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 522

Special Issue Editor

1. Laboratory of Experimental Neurology and Neuroimmunology, 2nd Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece
2. Laboratory of Histology and Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: neuroscience; multiple sclerosis; experimental autoimmune encephalomyelitis; intrathecal transplantation; stem cell differentiation; immunohistopathology; in situ hybridization; electron microscopy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Multiple sclerosis (MS) is an inflammation-based, chronic demyelinating disease of the central nervous system (CNS), with myelin degeneration and axonopathy being the major neuropathological hallmarks. Since the etiology of MS is still unknown and symptoms exhibit high heterogeneity among the individuals diagnosed, there exists a need to establish new biomarkers and to prioritize the development of research in animal models of MS, particularly at the molecular level.

Despite their limitations, CD4+-driven experimental autoimmune encephalomyelitis (EAE), Theiler׳s murine encephalomyelitis virus (TMEV) infection, and chemically induced demyelination (cuprizone, lysolecithin), individually reflect immunological pathogenesis, axonal impairment, and remyelination processes in MS. Furthermore, EAE can be outstandingly insightful in molecular research of potential experimental treatments, alongside immunogenetics and histopathology.

I hereby invite authors to submit original research or review articles on the molecular mechanisms underlying the pathogenesis of MS or its experimental models in the context of this Special Issue, entitled “Molecular research in multiple sclerosis”. Every submission will undergo meticulous, delay-free scrutiny, in accordance with the standards of the journal.

Dr. Paschalis Theotokis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • multiple sclerosis
  • inflammatory demyelination
  • molecular mechanisms
  • oligodendrocyte apoptosis
  • neurite outgrowth inhibition
  • immune regulation
  • microglia and macrophages
  • experimental autoimmune encephalomyelitis
  • therapeutic intervention
  • remyelination

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop